



Newfoundland and Labrador Pharmacy Board

Guidance Document

Guidelines Regarding the Sale of Dimenhydrinate

Issued November 2014

1. As a Schedule III drug, dimenhydrinate may be sold from the self-selection area of the pharmacy. However, even if sold from this location, registrants and other staff should be aware of the sales of dimenhydrinate and the pharmacist-in-charge should be alerted to any potential concerns or issues.
2. If evidence of misuse or abuse of dimenhydrinate is detected, pharmacists-in-charge are encouraged to restrict the sale of dimenhydrinate to Schedule II status (i.e. no patient selfselection, mandatory direct pharmacist involvement in the sale).
3. Dimenhydrinate in package sizes greater than 30 tablets, or 100ml of liquid should not be sold from the self-selection area of the pharmacy and should only be sold pursuant to a prescription, or following pharmacist assessment and documentation on the patient profile.